Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.8.4679

ERCC1 Expression Does Not Predict Survival and Treatment Response in Advanced Stage Non-Small Cell Lung Cancer Cases Treated with Platinum Based Chemotherapy  

Ozdemir, Ozer (Department of Chest Diseases, Ege University Faculty of Medicine)
Ozdemir, Pelin (Department of Chest Diseases, Ege University Faculty of Medicine)
Veral, Ali (Department of Pathology, Ege University Faculty of Medicine)
Uluer, Hatice (Department of Biostatistics, Ege University Faculty of Medicine)
Ozhan, Mustafa Hikmet (Department of Chest Diseases, Ege University Faculty of Medicine)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.8, 2013 , pp. 4679-4683 More about this Journal
Abstract
Background: ERCC1 is considered as a promising molecular marker that may predict platinum based chemotherapy response in non small cell lung cancer patients. We therefore investigated whether its expression is indeed associated with clinical outcomes in advanced stage NSCLC patients. Materials and Methods: Pretreatment tumor biopsy samples of 83 stage 3B and 4 non-small cell lung cancer patients treated with platinum based chemotherapy were retrospectively analyzed for immunohistochemical ERCC1 expression. None of the patients received curative surgery or radiotherapy. Results: By calculating H- scores regarding the extent and intensity of immunohistochemical staining of tumor biopsy samples, ERCC1 expression was found to be positive in 50 patients (60.2%). ERCC1 positive and negative groups had no statistically significant differences regarding treatment response, progression free survival and overall survival (respectively p=0.161; p=0.412; p=0.823). Conclusions: In our study we found no association between ERCC1 expression and survival or treatment response. The study has some limitations, such as small sample size and retrospective analysis method. There is need of more knowledge for use of ERCC1 guided chemotherapy regimens in advanced stage NSCLC.
Keywords
Non-small cell lung cancer; lung cancer chemotherapy; ERCC1; molecular markers;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Bepler G, Gautam A, McIntyre LM, et al (2002). Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J Clin Oncol, 20, 1353-60.   DOI   ScienceOn
2 Bepler G, Begum M, Simon GR (2008). Molecular analysis-based treatment strategies for non-small cell lung cancer. Cancer Control, 15, 130-9.
3 Bepler G, Williams C, Schell MJ, et al (2013). Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol, 31, 2404-12.   DOI   ScienceOn
4 Breen D, Barlesi F (2008). The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer. Eur J Cardiothorac Surg, 33, 805-11.   DOI   ScienceOn
5 Ceppi P, Volante M, Novello S, et al (2006). ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol, 17, 1818-25.   DOI   ScienceOn
6 Chen S, Zhang J, Wang R, Luo X, Chen H (2010). The platinum based treatments for advanced nonsmall cell lung cancer, is low/negative ERCC1 expression beter than high/positive ERCC1 expression? A metaanalysis. Lung Cancer, 70, 63-70.   DOI   ScienceOn
7 Fink D, Zheng H, Nebel S (1997). In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res, 57, 1841-5.
8 Friboulet L, Olaussen KA, Pignon JP, et al (2013). ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med, 368, 1101-10.   DOI   ScienceOn
9 Gao Z, Han B, Shen J, et al (2011). ERCC1 protein as a guide for individualized chemotherapy of late stage advanced non small cell lung cancer. Exp Ther Med, 2, 811-15.
10 Gomez-Roca C, Raynaud CM, Penault-Llorca F, et al (2009). Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol, 4, 1212-20.   DOI
11 Greene FL, Page DL, Fleming ID, et al (2002). AJCC Cancer Staging Manual. 6th ed. Springer: New York.
12 Groome PA, Bolejack V, Crowley JJ, et al (2007). The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (7th) edition of the TNM classification of malignant tumours. J Thorac Oncol, 2, 694-705.   DOI
13 Italiano A, Burel-Vandenbos F, Otto J (2006). Comparison of the epidermal growth factor receptor gene and protein in primary nonsmall-cell lung cancer and metastatic sites: implications for treatment with EGFR inhibitors. Ann Oncol, 17, 981-5.   DOI   ScienceOn
14 Lee HW, Choi YW, Han JH, et al (2009). Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum based doublet chemotherapy. Lung Cancer, 65, 377-82.   DOI   ScienceOn
15 Lord RV, Brabender J, Gandara D, et al (2002). Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res, 8, 2286-91.
16 Ludovic C, Gillet J, Scharer OD (2006). Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem Rev, 106, 253-76.   DOI   ScienceOn
17 Rosell R, Taron M, Barnadas A, et al (2003). Nucleotide excision repair pathways involved in cisplatin resistance in non-small-cell lung cancer. Cancer Control, 10, 297-305.
18 Martin LP, Hamilton TC, Schilder RJ (2008). Platinum resistance: The role of DNA repair pathways. Clin Cancer Res, 14, 1291-5.   DOI   ScienceOn
19 Olaussen KA, Dunant A, Fouret P, et al (2006). DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 355, 983-91.   DOI   ScienceOn
20 Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.   DOI   ScienceOn
21 Roth JA, Carlson JJ (2011). The prognostic role of ERCC1 in advanced non-small cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer, 12, 393-401.   DOI   ScienceOn
22 Sekine I, Minna JD, Nishio K, Tamura T, Saijo N (2006). A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer. J Thorac Oncol, 1, 31-7.   DOI
23 Simon GR, Ismail-Khan R, Bepler G (2007). Nuclear excision repair-based personalized therapy for non-small cell lung cancer: From hypothesis to reality. Int J Biochem & Cell Biology, 39, 1318-28.   DOI   ScienceOn
24 Taillade L, Penault-Llorca F, Boulet T, et al (2007). Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol, 18, 1043-50.   DOI   ScienceOn
25 van Zandwijk N (2001). Neoadjuvant strategies for non-small cell lung cancer. Lung Cancer, 34, 145-50.   DOI   ScienceOn
26 Zheng Z, Chen T, Li X, et al (2007). DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med, 356, 800-8.   DOI   ScienceOn